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Lafora disease (LD) is rare, fatal, autosomal recessive progressive myoclonic epilepsy which results from 
carbohydrate accumulations in many tissues. We report a case of LD in a 14-year old adolescent associating 
aggravating neurological manifestations and non auto-immune diabetes.  
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A 13-year-old boy was transferred to our department for 
evaluation and management of seizures. His personal and family 
medical history is unremarkable, particularly for neurologic or 
metabolic disorders. His physical exam was normal, but the 
electroencephalogram recording showed many subclinical, 
paroxystic and photosensitive generalized spikes waves. A 
multidrug therapy was initiated, with progressive clinical and 
electrical impairment (figure), and the diagnostic of progressive 
myoclonic epilepsy was suspected. Six months later, the 
diagnosis of non-autoimmune diabetes was made, requiring a 
very low dose of long-acting insulin. Testing for maturity onset 
diabetes of the young (MODY) found no mutations (table).  
A retinal dystrophy was noted on electroretinogram and the skin 
biopsy found glycogen inclusions in the excretory ducts of 
eccrine sweat glands. Two years after the first signs of epilepsy, 
LD was confirmed with evidence of a c.386C> A p (Pro 129 His) 
mutation in the malin EMP2B gene. A new evaluation of 
pancreatic endocrine secretion showed a certain insulin 
resistance, with no pancreatic antibodies. Diabetes therapy was 
temporary switched to metformine, with satisfactory metabolic 
profile, but some side effects.  
Lafora disease is a progressive myoclonus 
epilepsy beginning in late childhood with a 
typical clinical course. Abnormal glycogen 
metabolism and autophagy account for 
multiorgan accumulation of Lafora bodies 
with neurodegeneration and possible 
functional consequences (insulin resistance). 
The glycemic disorders reported in our patient 
do not correspond to a type of diabetes 
known, a coincidence between these two 
pathologies remains  so unlikely. 
Introduction  
Case report  
Figure: evolution of the electroencephalogram (EEG); above, initial EEG 
with paroxysmal generalized spike-waves complexes; below, EEG 2 years 
later with generalized slowdown associated with multiple paroxysmal 
complexes 
Conclusion 
Table: Patient’s diabetes – insulin secretion and treatment ; T1DM – type 1 diabetes mellitus, HbA1c - 
glycated haemoglobin, ICA - islet cell antibodies, GAD65 - antibodies to glutamic acid decarboxylase, 
IAA -  insulin autoantibodies, ZnT8 -  zinc transporter 8 autoantibodies, MODY - maturity onset diabetes 
of the young, T2DM – type 2 diabetes mellitus 
  Weights Biological profile Treatment Remarks 
  
At diabetes diagnosis 
  




Blood sugar 200 mg/dl (60 – 100mg/dl) 
Insulin 15.7 mU/l (2 – 17 mU/l) 
C peptide 0.93 nmol/l (0.37 – 1.47 nmol/l) 
HbA1c 7.5% (4 – 6%) 
Negative autoimmune markers 
(ICA, GAD65, IAA, ZnT8) 





after diabetes diagnosis 




after diabetes diagnosis 
  No MODY mutations 
(GCK, HNF1A, HNF4A, HNF1B, ABCC8, 
KCNJ11, INS) 




after diabetes diagnosis 
48 kg HbA1c 6.5% Neither  insulin, nor  other 
diabetes  treatment 
Diabetes mellitus, 
but not T1DM 
Lafora diagnosis 
(24 months after the 
first seizure) 
50 kg Insulin 29.4 mUI/l 
C peptide 1.62 nmol/l 
(patient´s own secretion) 
HbA1c 8.2% 




after diabetes diagnosis 
  
52 kg Blood sugar 200 – 300 mg/dl 
C peptide 1.8 nmol/l 
Negative pancreatic antibodies 
HbA1c 8.3% 
Metformin 1500 mg/d Insulin 
resistance/T2DM 
40 months 
after diabetes diagnosis 
52 kg Blood sugar 170 – 200 mg/dl 
C peptide 0,9 nmol/l 
Insulin 12 mUI/l 
HbA1c 7,6% 
Metformin 1000 mg/d Insulin 
resistance/T2DM 
